The FDA Should Not Enforce the 5th Circuit’s Indefensible Abortion Pill Decision

attempting to cut off access to mifepristone, the first drug in a medication abortion. Even the 5th Circuit could not defend Kacsmaryk’s attempt to revoke the FDA’s approval of the drug, which it granted in 2000. But the appeals court agreed with him on nearly everything else, imperiling access to abortion in blue states.

But they got lucky: The randomly assigned 5th Circuit panel included Andrew Oldham and Kurt Engelhardt, two of the most extreme Donald Trump appointees in the entire federal judiciary. The ruling was obviously written by Oldham, as it bears all the judge’s rhetorical trademarks. These plaintiffs really could not have hoped for a more favorable judge to adjudicate their case.

statute of limitations for challenging such an agency action bars an attack on the original approval of mifepristone in 2000. So instead, the appeals court suspends every FDA approval related to the drug since 2016.

If that’s true, then it lays the groundwork for a federal ban on abortion. All means of abortion invariably go through interstate commerce. Pills must be shipped to providers, even if they are not ultimately mailed to patients. The medical instruments used in procedural abortions must travel across state lines to reach their destination. In a modern economy, it is just inevitable thatdesigned for abortion will go through interstate commerce.

I hate this for you.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Court Partially Halts Ruling Restricting Access to Abortion PillA hardline conservative judge suspended the FDA’s approval of the drug last Friday. hardline as jn radical comunist right wing
Source: thedailybeast - 🏆 307. / 63 Read more »

Clinical trial participant’s autopsy and brain exam stoke Alzheimer’s drug fearsThe brain of a woman who died after receiving a new Alzheimers disease drug has deepened some researchers’ concerns that lecanemab poses serious risks for patients. If I had alzheimers, I would probably want to take any risk to fight it, it's a horrible disease. Hopefully the drug is still promising. Is the drug as risky as… oh I don’t know…. Having Alzheimer’s? This is important research. Lecanemab is a great second step. I'm watching ProMISinc and their PMN310 closely. Impressive data at AD/PD 2023 showing higher selectivity and potentially lower ARIA-E risk due to less off-target binding $PMN
Source: NewsfromScience - 🏆 515. / 51 Read more »

The Comstock Act is no solution for pro-lifers or the FDA's bureaucratic rotIn a Friday afternoon news dump, Judge Matthew Kacsmaryk struck down the Food and Drug Administration's approval of mifepristone more than 20 years ago. Although a separate judge tried to oppose Kacsmaryk’s ruling, the FDA’s approval will inevitably face the highest court in the land. While some…
Source: dcexaminer - 🏆 6. / 94 Read more »